Exelixis gained an exclusive option to license XB002 (then ICON-2) in exchange for an upfront ... The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at ...
We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients with metastatic melanoma who were refractory or resistant to PD-1 inhibitors. We are ...
Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds ...
The data was still under wraps at that time, but has just been revealed in the ESMO congress abstract drop – a 3.2 month improvement over control, compared to 1.6 months at ASCO. Taken in ...
AZoM on MSN2h
esmo group launches Apollo Quad Handleresmo group has launched its latest product—the Apollo Quad Handler. Designed to bridge the gap between the engineering and ...
Simon Wentworth is a journalist and digital news editor at The Pharma Letter. Part of the editorial team since 2017, Simon is host of The Pharma Letter Podcast and has reported from major European and ...
The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback